Debt-to-equity of Keros Therapeutics, Inc. from 30 Sep 2020 to 31 Dec 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Keros Therapeutics, Inc. quarterly Debt-to-equity in % history and change rate from 30 Sep 2020 to 31 Dec 2025.
  • Keros Therapeutics, Inc. Debt-to-equity for the quarter ending 31 Dec 2025 was 7.4%, a 6.8% decline year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

Keros Therapeutics, Inc. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q4 2025 7.4% -0.54% -6.8% 31 Dec 2025
Q3 2025 7% -1.6% -19% 30 Sep 2025
Q2 2025 7.8% -1.2% -13% 30 Jun 2025
Q1 2025 8% -1.2% -13% 31 Mar 2025
Q4 2024 7.9% -1.8% -19% 31 Dec 2024
Q3 2024 8.6% -0.87% -9.2% 30 Sep 2024
Q2 2024 8.9% +0.56% +6.7% 30 Jun 2024
Q1 2024 9.2% +1.3% +17% 31 Mar 2024
Q4 2023 9.8% +2.6% +37% 31 Dec 2023
Q3 2023 9.5% +4% +72% 30 Sep 2023
Q2 2023 8.4% +2.7% +48% 30 Jun 2023
Q1 2023 7.9% +3.2% +69% 31 Mar 2023
Q4 2022 7.1% +2.8% +66% 31 Dec 2022
Q3 2022 5.5% +1.8% +46% 30 Sep 2022
Q2 2022 5.6% +2% +53% 30 Jun 2022
Q1 2022 4.7% +0.37% +8.6% 31 Mar 2022
Q4 2021 4.3% -2.4% -36% 31 Dec 2021
Q3 2021 3.8% -12% -77% 30 Sep 2021
Q2 2021 3.7% 30 Jun 2021
Q1 2021 4.3% 31 Mar 2021
Q4 2020 6.7% 31 Dec 2020
Q3 2020 16% 30 Sep 2020
* An asterisk sign (*) next to the value indicates that the value is likely invalid.